Platform & Pipeline
Patients
Inside Kyverna
- Leadership
- Mission & Values
Education & Events
- Publications
- Videos
Investors
News
Careers
Contact

CD19-targeted CAR T cells in refractory antisynthetase syndrome

by Creative Pace | Dec 3, 2023

Search

About

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.

Our lead CAR T-cell therapy candidate mivocabtagene (miv-cel, KYV-101), is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.

Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

FOLLOW US ON SOCIAL

Privacy Policy (US)
Privacy Policy (EU/UK)

Designed by Elegant Themes | Powered by WordPress

CD19-targeted CAR T cells in refractory antisynthetase syndrome

Recent Comments